| 产品描述: | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas. |
| 体内研究: |
Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) 均可以显著抑制肿瘤的生长,延长小鼠的生存周期,具有有效的体内抗肿瘤活性。 |
| 参考文献: |
1. Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845.
|
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0 ml |
0 ml |
0 ml |
| 5 mM |
0 ml |
0 ml |
0 ml |
| 10 mM |
0 ml |
0 ml |
0 ml |
| 50 mM |
0 ml |
0 ml |
0 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |